Clariant, a world leader in specialty chemicals, and SICPA SA, a provider of global security solutions, joined hands to develop and launch PLASTIWARD™, a robust integrated protection for plastic pharmaceutical packaging or medical devices.
Steve Duckworth, Head of Global Segment Healthcare Polymer Solutions at Clariant explained, “PLASTIWARD offers medical-device and pharmaceutical packaging companies a two-in-one approach. It combines Clariant’s track record in developing polymer compounds and masterbatches tailored to the unique requirements of clients in those sectors with SICPA’s proven expertise in protecting brands and products. As part of the PLASTIWARD value proposition, our unique solution offers clients one seamless package comprising: security assessment, the definition of their needs, security system design, system deployment and on-going performance monitoring.”
The chronic problems from diabetes to asthma make use of portable plastic pharmaceutical packagings such as insulin pens or inhalers for targeted delivery of treatment. Estimates show that a CAGR of 6.5% for the global medical devices market from 2014 to 2020, rising from an estimated USD 61 billion in 2014 to USD 89 billion in 2020. This has attracted counterfeiters who are often part of organized crime syndicates producing fakes which are often very difficult to differentiate from legitimate products, often escaping customs inspections. Such products pose a health risk for the patients who rely on them to manage a life-threatening condition.
“At Clariant, our 3C approach (Controlled, Consistent, Compliant) with our MEVOPUR products for the medical and pharmaceutical sectors is based on helping to control and minimize risks of potential changes and regulatory non-compliance- supply chain,” Duckworth said. “PLASTIWARD can add another element of risk reduction and protection, providing a robust, cost-effective, end-to-end, in-plastic system for protecting your brands worldwide.”